UB Paderborn / Katalog / Suche / in CDI

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide

The Prostate, 2023-03, Vol.83 (4), p.376-384

2023

Volltextzugriff (PDF)

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2022-03, Vol.386 (12), p.1132-1142

2022

Volltextzugriff (PDF)

Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

Clinical genitourinary cancer, 2022-02, Vol.20 (1), p.25-34

2022

Volltextzugriff (PDF)

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

The New England journal of medicine, 2021-04, Vol.384 (14), p.1289-1300

2021

Volltextzugriff (PDF)

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

European journal of cancer (1990), 2022-09, Vol.173, p.317-326

2022

Volltextzugriff (PDF)

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

The New England journal of medicine, 2021-04, Vol.384 (14), p.1289-1300

2021

Volltextzugriff (PDF)

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

European urology oncology, 2021-06, Vol.4 (3), p.456-463

2021

Volltextzugriff (PDF)

Cardiac tumors. Experience with two cases

Anales de pediatría (Barcelona, Spain : 2003), 2004-07, Vol.61 (1), p.69

2004

Volltextzugriff (PDF)

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases

The Prostate, 2019-10, Vol.79 (14), p.1683-1691

2019

Volltextzugriff (PDF)

Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain

Clinical & translational oncology, 2022-03, Vol.24 (3), p.495-502

2022

Volltextzugriff (PDF)

Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer

Journal of clinical medicine, 2019-11, Vol.8 (12), p.2056

2019

Volltextzugriff (PDF)

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

BMC cancer, 2016-02, Vol.16 (136), p.135-135, Article 135

2016

Volltextzugriff (PDF)

Whole-exome sequencing identifies novel compound heterozygous mutations in USH2A in Spanish patients with autosomal recessive retinitis pigmentosa

Molecular vision, 2013-11, Vol.19, p.2187-2195

2013

Volltextzugriff (PDF)

Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.269-269

2021

Volltextzugriff (PDF)

ECO Experts’ consensus on establishing renal cancer healthcare quality measures in Spain

Journal of clinical oncology, 2020-10, Vol.38 (29_suppl), p.220-220

2020

Volltextzugriff (PDF)

MP52-04 2-YEAR FOLLOW-UP OF RADIUM-223 RE-TREATMENT IN AN INTERNATIONAL, OPEN-LABEL, PHASE 1/2 STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND BONE METASTASES

The Journal of urology, 2018-04, Vol.199 (4), p.e695-e696

2018

Volltextzugriff (PDF)

Evaluation of an automated wavelet-based system dedicated to the detection of clustered microcalcifications in digital mammograms

Medical informatics and the internet in medicine, 2001, Vol.26 (3), p.149-163

2001

Volltextzugriff (PDF)

MP50-16 RADIUM-223 RE-TREATMENT: EXPERIENCE FROM AN INTERNATIONAL, MULTICENTER, PROSPECTIVE STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND BONE METASTASES

The Journal of urology, 2016-04, Vol.195 (4), p.e678-e679

2016

Volltextzugriff (PDF)

Expert consensus on the development of quality care measures for kidney cancer in Spain

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e19180-e19180

2020

Volltextzugriff (PDF)

Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4502-4502

2021

Volltextzugriff (PDF)

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4506-4506

2018

Volltextzugriff (PDF)

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

The New England journal of medicine, 2023-05, Vol.388 (19), p.1767-1778

2023

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

Cardiac tumors. Experience with two cases

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases

Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain

Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

Whole-exome sequencing identifies novel compound heterozygous mutations in USH2A in Spanish patients with autosomal recessive retinitis pigmentosa

Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)

ECO Experts’ consensus on establishing renal cancer healthcare quality measures in Spain

MP52-04 2-YEAR FOLLOW-UP OF RADIUM-223 RE-TREATMENT IN AN INTERNATIONAL, OPEN-LABEL, PHASE 1/2 STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND BONE METASTASES

Evaluation of an automated wavelet-based system dedicated to the detection of clustered microcalcifications in digital mammograms

MP50-16 RADIUM-223 RE-TREATMENT: EXPERIENCE FROM AN INTERNATIONAL, MULTICENTER, PROSPECTIVE STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND BONE METASTASES

Expert consensus on the development of quality care measures for kidney cancer in Spain

Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS)

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Suchergebnisse filtern